Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here are three stocks where Wall Street’s estimates seem disconnected from reality and some better opportunities to consider.
USANA (USNA)
Consensus Price Target: $39 (117% implied return)
Going to market with a direct selling model rather than through traditional retailers, USANA Health Sciences (NYSE: USNA) manufactures and sells nutritional, personal care, and skincare products.
Why Are We Cautious About USNA?
- Annual sales declines of 1.7% for the past three years show its products struggled to connect with the market
- Subscale operations are evident in its revenue base of $925.9 million, meaning it has fewer distribution channels than its larger rivals
- Earnings per share decreased by more than its revenue over the last three years, showing each sale was less profitable
USANA’s stock price of $18 implies a valuation ratio of 8.4x forward P/E. Read our free research report to see why you should think twice about including USNA in your portfolio.
GEO Group (GEO)
Consensus Price Target: $29.50 (20.4% implied return)
With a global footprint spanning three continents and approximately 81,000 beds across 100 facilities, GEO Group (NYSE: GEO) operates secure facilities, processing centers, and reentry services for government agencies in the United States, Australia, and South Africa.
Why Does GEO Fall Short?
- Annual revenue growth of 3.3% over the last five years was below our standards for the business services sector
- Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 4 percentage points
- Free cash flow margin dropped by 11.1 percentage points over the last five years, implying the company became more capital intensive as competition picked up
GEO Group is trading at $24.50 per share, or 1.1x forward price-to-sales. Dive into our free research report to see why there are better opportunities than GEO.
Core Laboratories (CLB)
Consensus Price Target: $16.33 (26.3% implied return)
With roots dating back to the first commercial oil boom, Core Laboratories (NYSE: CLB) analyzes rock and fluid samples from oil and gas reservoirs to help energy companies optimize production and recovery.
Why Are We Out on CLB?
- Muted 3.4% annual revenue growth over the last five years shows its demand lagged behind its energy upstream and integrated energy peers
- Subscale operations are evident in its revenue base of $524.7 million, meaning it has fewer distribution channels than its larger rivals
- High extraction costs and unfavorable asset economics are reflected in its low gross margin of 20.4%
At $12.93 per share, Core Laboratories trades at 1.2x forward price-to-sales. Check out our free in-depth research report to learn more about why CLB doesn’t pass our bar.
Stocks We Like More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
